8-K: Elite Pharmaceuticals Launches Generic Version of Tylenol with Codeine

Elite Pharmaceuticals has announced the commercial launch of its generic version of Tylenol with Codeine tablets.

Summary

• Elite Pharmaceuticals has launched its generic version of Tylenol with Codeine, which includes acetaminophen and codeine phosphate tablets in 300mg/15mg, 300mg/30mg, and 300mg/60mg dosages.
• The product is being marketed and sold under the Elite Laboratories, Inc. label.
• These tablets are indicated for the management of mild to moderate pain where opioid treatment is appropriate and alternative treatments are inadequate.
• According to IQVIA, the total U.S. sales for acetaminophen and codeine tablets in these dosages was approximately $47 million for the 12 months ending May 2024.

Sentiment

Score: 7

Explanation: The announcement is positive as it indicates a new product launch and revenue opportunity, but it also carries the usual risks associated with the pharmaceutical industry and generic drug competition.

Positives

• The launch of a generic version of Tylenol with Codeine provides a new revenue stream for Elite Pharmaceuticals.
• The product addresses a market with approximately $47 million in annual sales, indicating a significant market opportunity.
• Elite is leveraging its existing manufacturing and distribution capabilities to bring this product to market.

Risks

• The press release contains forward-looking statements that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially.
• The company is subject to FDA approval processes and potential actions required by the FDA to obtain approvals.
• The company faces competition in the generic pharmaceutical market.

Future Outlook

The company's future performance is subject to risks and uncertainties, including FDA approvals and market competition. The company is under no obligation to update or alter its forward-looking statements.

Management Comments

• Elite Pharmaceuticals, Inc. announced that the company has launched Elite's generic version of Tylenol with Codeine.

Industry Context

The launch of a generic version of Tylenol with Codeine is a common strategy in the pharmaceutical industry, where companies seek to capitalize on off-patent drugs. This launch positions Elite Pharmaceuticals in the competitive generic pain management market.

Comparison to Industry Standards

• The $47 million market size for acetaminophen and codeine tablets indicates a moderate-sized market for generic pharmaceutical companies.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) are major players in the generic drug market and would be considered competitors in this space.
• The success of Elite's product will depend on its ability to compete on price, quality, and distribution.

Stakeholder Impact

• Shareholders may view this product launch positively as it represents a potential revenue stream.
• Customers will have access to a generic alternative for pain management.
• Employees may benefit from the company's growth and expansion.

Key Dates

Keywords

generic drugs, pharmaceuticals, acetaminophen, codeine, pain management, opioids, Elite Pharmaceuticals, Elite Laboratories